Glucose Monitors Help People With Type 2 Diabetes, Major Trial Finds

Continuous glucose monitors — the small wearable sensors that track blood sugar around the clock — have transformed life for many people with type 1 diabetes. Now the largest clinical trial of its kind suggests they could do far more for people with type 2 diabetes as well, including those who do not use insulin. The trial, published in the New England Journal of Medicine, found that adults with type 2 diabetes who used a continuous glucose monitor (CGM) spent approximately five more hours a day within their target blood sugar range than those relying on conventional monitoring — a difference researchers say is large enough to matter for long-term health.

What the Trial Found

Most people with type 2 diabetes check their glucose with finger-stick tests, which provide a snapshot at a single moment. A CGM, by contrast, measures glucose in the fluid just under the skin every few minutes and sends a continuous stream of readings to a phone or receiver, complete with trend arrows showing whether levels are rising, falling or holding steady. In the trial, that constant feedback translated into roughly five extra hours a day spent in range — time when blood sugar was neither dangerously high nor low.

The result is striking partly because of who benefited. Participants were adults managing type 2 diabetes without insulin, a group for whom CGMs have often been considered unnecessary or hard to justify to insurers. The findings challenge that assumption, suggesting the value of the technology lies less in fine-tuning insulin doses and more in the everyday behaviour change that real-time feedback inspires: seeing exactly what a meal, a walk or a stressful afternoon does to your glucose, while you can still do something about it.

Why Time in Range Matters

Diabetes care has traditionally revolved around HbA1c, a blood test that reflects average glucose over about three months. “Time in range” is a newer measure that captures something HbA1c cannot: the daily swings. Two people can share the same average while one rides a rollercoaster of spikes and crashes and the other stays steady — and it is the spikes, researchers increasingly believe, that drive much of the damage to blood vessels, nerves, eyes and kidneys over time.

Five additional hours a day in range, compounded over months and years, could mean meaningfully less exposure to the high glucose that fuels those complications. It also means fewer energy-sapping swings day to day. As we explored in our look at the science of sleep and what the brain does while you rest, blood sugar, rest and daily rhythms are tightly intertwined — steadier glucose often goes hand in hand with steadier sleep and sharper mornings.

Who Stands to Benefit Most

Type 2 diabetes affects hundreds of millions of people worldwide, and the great majority do not use insulin. If CGMs help even a fraction of them stay in range longer, the public-health impact could be substantial. The people most likely to gain are those newly diagnosed, who are still building habits; people whose HbA1c remains above target despite oral medication; and anyone who finds finger-stick testing painful, inconvenient or easy to abandon. The American Diabetes Association already recommends CGMs for many people on insulin, and evidence like this trial is likely to fuel pressure to widen that guidance.

The Barriers Are Real

Enthusiasm should be tempered with practicality. Sensors must be replaced every 10 to 15 days, and out-of-pocket costs remain a barrier in many health systems. Some users find the constant data stressful rather than empowering, and a stream of numbers is only useful if patients are shown how to interpret it. There is also the risk of a two-tier system, in which the patients best placed to benefit are the least able to pay. Trials demonstrate what a technology can do under study conditions; health systems must still decide what it should do, and for whom, within real budgets.

Questions to Ask Your Doctor

If you live with type 2 diabetes, this research is a good prompt for a conversation — not a reason to order a sensor on impulse. Ask whether a short trial of CGM would help you understand your own patterns, whether your insurer or health system covers sensors for people not using insulin, and what target range makes sense for you personally. Bring your questions about cost, comfort and data overload; a good clinician will treat them as part of the prescription.

The deeper message of the trial is not really about a gadget. It is about feedback: people manage what they can see. For decades, most people with type 2 diabetes have been asked to steer their blood sugar while looking through a keyhole a few times a day. Continuous monitors throw the door open — and, if this evidence holds, hours of healthier days may follow.